低剂量达芦那韦/利托那韦在有蛋白酶抑制剂治疗史的 HIV 感染患者中有效。
A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients.
机构信息
Infectious Diseases Unit, G.B. Rossi Hospital, Via piazzale L. Scuro 10, Verona, Italy.
出版信息
Braz J Infect Dis. 2011 Sep-Oct;15(5):498-500.
Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIV-positive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
达芦那韦（DRV）是一种 HIV-1 蛋白酶抑制剂，与低剂量利托那韦联合使用，作为治疗经验丰富和初治 HIV 阳性患者的抗逆转录病毒治疗（ART）方案的一部分。在无 DRV 突变的初治和经验丰富的患者中，DRV 的批准剂量为 800mg 加 100mg 利托那韦，每日一次。我们报告了 7 例接受 ART 治疗的 HIV 感染患者的结果，他们接受了达芦那韦/利托那韦（600/100mg，每日一次）的低剂量治疗，成功控制了病毒复制。
Zotero 插件